BACKGROUND: Natalizumab is an antibody directed against integrin alpha4 that reduces disease activity in patients with multiple sclerosis (MS) by blocking migration of T and B cells into the CNS. The goal of this study was to characterize the effects of natalizumab treatment on cytokine production and expression of activation markers, costimulatory molecules, and trafficking determinants on CD4+ and CD8+ T cells. METHODS: In a longitudinal study, we investigated the expression of surface makers and cytokine expression on peripheral blood lymphocytes from 28 patients with MS who started natalizumab treatment and were followed for 1 year. A mixed effects model was used to compare pretreatment to on-treatment measurements. RESULTS: The frequency of CD4+ T cells producing interferon-gamma, tumor necrosis factor, and interleukin (IL)-17 upon anti-CD3 stimulation increased 6 months after initiation of natalizumab treatment and remained elevated throughout the follow-up. The frequency of CD4+ T cells expressing CD25, HLA-DR, and CCR6 ex vivo was increased at one or more time points during treatment. Among CD8+ T cells, the frequency of cells producing IL-2 and IL-17 after stimulation was increased during natalizumab treatment, as was the frequency of CD8+ T cells expressing CD58 and CCR5 ex vivo. The increase in the frequency of activated cells could not be replicated by in vitro exposure to natalizumab. CONCLUSION: Natalizumab treatment increases the percentage of activated leukocytes producing proinflammatory cytokines in blood, presumably due to sequestration of activated cells in the peripheral circulation.
BACKGROUND:Natalizumab is an antibody directed against integrin alpha4 that reduces disease activity in patients with multiple sclerosis (MS) by blocking migration of T and B cells into the CNS. The goal of this study was to characterize the effects of natalizumab treatment on cytokine production and expression of activation markers, costimulatory molecules, and trafficking determinants on CD4+ and CD8+ T cells. METHODS: In a longitudinal study, we investigated the expression of surface makers and cytokine expression on peripheral blood lymphocytes from 28 patients with MS who started natalizumab treatment and were followed for 1 year. A mixed effects model was used to compare pretreatment to on-treatment measurements. RESULTS: The frequency of CD4+ T cells producing interferon-gamma, tumornecrosis factor, and interleukin (IL)-17 upon anti-CD3 stimulation increased 6 months after initiation of natalizumab treatment and remained elevated throughout the follow-up. The frequency of CD4+ T cells expressing CD25, HLA-DR, and CCR6 ex vivo was increased at one or more time points during treatment. Among CD8+ T cells, the frequency of cells producing IL-2 and IL-17 after stimulation was increased during natalizumab treatment, as was the frequency of CD8+ T cells expressing CD58 and CCR5 ex vivo. The increase in the frequency of activated cells could not be replicated by in vitro exposure to natalizumab. CONCLUSION:Natalizumab treatment increases the percentage of activated leukocytes producing proinflammatory cytokines in blood, presumably due to sequestration of activated cells in the peripheral circulation.
Authors: B E Theien; C L Vanderlugt; T N Eagar; C Nickerson-Nutter; R Nazareno; V K Kuchroo; S D Miller Journal: J Clin Invest Date: 2001-04 Impact factor: 14.808
Authors: Christopher Lock; Guy Hermans; Rosetta Pedotti; Andrea Brendolan; Eric Schadt; Hideki Garren; Annette Langer-Gould; Samuel Strober; Barbara Cannella; John Allard; Paul Klonowski; Angela Austin; Nagin Lad; Naftali Kaminski; Stephen J Galli; Jorge R Oksenberg; Cedric S Raine; Renu Heller; Lawrence Steinman Journal: Nat Med Date: 2002-05 Impact factor: 53.440
Authors: Bradley E Theien; Carol L Vanderlugt; Cheryl Nickerson-Nutter; Mark Cornebise; Daniel M Scott; Stuart J Perper; Eric T Whalley; Stephen D Miller Journal: Blood Date: 2003-08-21 Impact factor: 22.113
Authors: P W O'Connor; A Goodman; A J Willmer-Hulme; M A Libonati; L Metz; R S Murray; W A Sheremata; T L Vollmer; L A Stone Journal: Neurology Date: 2004-06-08 Impact factor: 9.910
Authors: David H Miller; Omar A Khan; William A Sheremata; Lance D Blumhardt; George P A Rice; Michele A Libonati; Allison J Willmer-Hulme; Catherine M Dalton; Katherine A Miszkiel; Paul W O'Connor Journal: N Engl J Med Date: 2003-01-02 Impact factor: 91.245
Authors: Niannian Ji; Nagarjun Rao; Neal M Guentzel; Bernard P Arulanandam; Thomas G Forsthuber Journal: J Immunol Date: 2011-01-26 Impact factor: 5.422
Authors: John N Ratchford; Regina Brock-Simmons; Amanda Augsburger; Sonya U Steele; Kristie Mohn; Mandi Rhone; Jinyan Bo; Kathleen Costello Journal: Int J MS Care Date: 2014
Authors: Miriam Mattoscio; Richard Nicholas; Maria P Sormani; Omar Malik; Jean S Lee; Adam D Waldman; Francesco Dazzi; Paolo A Muraro Journal: Neurology Date: 2015-03-11 Impact factor: 9.910